[미국특허]
Long-acting polypeptides and methods of producing and administering same
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/27
A61K-038/24
C07K-014/61
C07K-014/59
C07K-014/505
C07K-014/555
출원번호
US-0804354
(2013-03-14)
등록번호
US-8946155
(2015-02-03)
발명자
/ 주소
Fares, Fuad
Fima, Udi Eyal
출원인 / 주소
OPKO Biologics Ltd.
대리인 / 주소
Cohen, Mark S.
인용정보
피인용 횟수 :
2인용 특허 :
67
초록▼
A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using
A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
대표청구항▼
1. A method of reducing the dosing frequency of a growth hormone in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of a modified growth hormone with one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to
1. A method of reducing the dosing frequency of a growth hormone in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of a modified growth hormone with one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus of said growth hormone and two chorionic gonadotrophin CTPs attached to the carboxy terminus of said growth hormone, wherein said modified growth hormone optionally comprises a signal peptide attached to the amino terminus of said one CTP, and wherein the dosing frequency of said modified growth hormone is thereby reduced as compared to the dosing frequency of a corresponding unmodified growth hormone in a subject. 2. The method of claim 1, wherein the sequence of at least one CTP consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18. 3. The method of claim 1, wherein said at least one CTP is glycosylated. 4. The method of claim 1, wherein said at least one CTP is truncated. 5. The method of claim 1, wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19. 6. The method of claim 1, wherein at least one CTP is optionally attached to said growth hormone via a linker. 7. The method of claim 6, wherein the linker is a peptide bond. 8. The method of claim 1, wherein said modified growth hormone is administered once weekly, once every two weeks, or once every three weeks. 9. The method of claim 1, wherein said subject is a human subject. 10. The method of claim 1, wherein said growth hormone is human growth hormone (hGH). 11. The method of claim 1, wherein said modified growth hormone is administered via the subcutaneous route. 12. The method of claim 1, wherein said modified growth hormone is administered via the intravenous route. 13. The method of claim 1, wherein said modified growth hormone is administered at a dosage range of 0.01-50 mg/week. 14. The method of claim 1, wherein said modified growth hormone is administered at a dosage range of 0.1-20 mg/week. 15. The method of claim 1, wherein said modified growth hormone is administered at a dosage range of 0.1-10 mg/week. 16. The method of claim 1, wherein said modified growth hormone is administered at a dosage range of 0.5-50 mg/week. 17. A method of improving the area under the curve (AUC) of a growth hormone in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of a modified growth hormone with one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus of said growth hormone and two chorionic gonadotrophin CTPs attached to the carboxy terminus of said growth hormone, wherein said modified growth hormone optionally comprises a signal peptide attached to the amino terminus of said one CTP, and wherein the AUC of said modified growth hormone is thereby improved as compared to the AUC of a corresponding unmodified growth hormone in a subject. 18. The method of claim 17, wherein the sequence of at least one CTP consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18. 19. The method of claim 17, wherein said at least one CTP is glycosylated. 20. The method of claim 17, wherein said at least one CTP is truncated. 21. The method of claim 17, wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19. 22. The method of claim 17, wherein at least one CTP is optionally attached to said growth hormone via a linker. 23. The method of claim 22, wherein the linker is a peptide bond. 24. The method of claim 17, wherein said modified growth hormone is administered once weekly, once every two weeks, or once every three weeks. 25. The method of claim 17, wherein said subject is a human subject. 26. The method of claim 17, wherein said growth hormone is human growth hormone (hGH). 27. The method of claim 17, wherein said modified growth hormone is administered via the subcutaneous route. 28. The method of claim 17, wherein said modified growth hormone is administered via the intravenous route. 29. The method of claim 17, wherein said modified growth hormone is administered at a dosage range of 0.01-50 mg/week. 30. The method of claim 17, wherein said modified growth hormone is administered at a dosage range of 0.1-20 mg/week. 31. The method of claim 17, wherein said modified growth hormone is administered at a dosage range of 0.1-10 mg/week. 32. The method of claim 17, wherein said modified growth hormone is administered at a dosage range of 0.5-50 mg/week.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Lee, Dong-Eok; Oh, Myung-Suk; Kim, Ki-Wan; Chung, Bo-Sup; Ha, Byung-Jhip; Park, Ji-Sook, Fusion protein having the enhanced in vivo activity of erythropoietin.
Wands Jack R. (Waban MA) Zurawski ; Jr. Vincent R. (West Chester PA) Schoemaker ; Hubert J. P. (Newton MA), Immunoassay utilizing monoclonal high affinity IgM antibodies.
Smulson Mark E. (Washington DC) Bhatia Kishor (Arbutus MD) Huppi Konrad (Reston VA), Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for hu.
Klima,Horst; Lehmann,Paul; Roeddiger,Ralf; Walter Matsui,Ruth, Method of treating disturbances of iron distribution in inflammatory intestinal diseases.
Boime Irving ; Menahem David Ben, Single chain glycoprotein hormones comprising two .beta. and one .alpha. subunits and recombinant production thereof.
Mark David F. (Danville CA) Lin Leo S. (Fremont CA) Yu Lu Shi-Da (Oakland CA), Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins.
Selden Richard F. ; Borowski Marianne ; Gillispie Frances P. ; Kinoshita Carol M. ; Treco Douglas A. ; Williams Melanie D., Tranfected human cells expressing human .alpha.-galactosidase A protein.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.